2012 — 2026
News
Every item keeps its original title and publication date, with a short note on what it does — and does not — establish.
Titles are shown as originally published (English).
2026
- Grant
Ossianix Receives Fast Forward Funding from National MS Society
US$0.8m Fast Forward support for preclinical brain-penetrant anti-CD20 work. Not clinical endorsement.
Read on ossianix.co.uk ↗
2025
- Grant
Ossianix Receives Grant from The Michael J. Fox Foundation to Advance TXP1 Brain Shuttle for Delivering TrkB Agonist Antibody in Parkinson’s Disease Therapy
US$1.26m MJFF support for preclinical TXP1-TrkB development (MJFF funding year 2024). Not clinical endorsement.
Read on ossianix.co.uk ↗
2022
- Agreement
Attralus and Ossianix Announce an Option and License Agreement using the TXP1 Brain Shuttle for Targeted Delivery of AT-04, a Pan-Amyloid Removal Therapeutic, for Neurodegenerative Disorders
Option/licence announcement pairing AT-04 with TXP1. Current status not established.
Read on ossianix.co.uk ↗
2020
- Data
Ossianix to Present Preclinical Data Demonstrating Best-in-Class Blood Brain Barrier Delivery in Non-Human Primates by Single Domain VNAR Antibodies
Reported NHP delivery experiment (>30-fold in hippocampus under specified conditions). Not human data.
Read on ossianix.co.uk ↗ - COVID-19 (2020)
Ossianix awarded Pennsylvanian Wolf Administration Award to develop COVID-19 vaccine.
Historical 2020 research or award news. Not a current vaccine or treatment.
Read on ossianix.co.uk ↗ - COVID-19 (2020)
Ossianix is responding to the COVID-19 pandemic by developing therapeutic single domain VNAR antibodies to the COVID-19 spike protein.
Historical 2020 research or award news. Not a current vaccine or treatment.
Read on ossianix.co.uk ↗
2018
- Agreement
Ossianix - Novo Nordisk Press Release
Historical research/option agreement. Continuation not established.
Read on ossianix.co.uk ↗ - Media & events
Ossianix Featured in Bold Business
Historical media coverage or conference presentation.
Read on ossianix.co.uk ↗ - Media & events
Ossianix gets mentioned in Science Magazine
Historical media coverage or conference presentation.
Read on ossianix.co.uk ↗
2017
- Media & events
Biopharma Reporter on our BBB-shuttle technology
Historical media coverage or conference presentation.
Read on ossianix.co.uk ↗ - Lundbeck
Reuters and FierceBiotech on Ossianix-Lundbeck partnership
Historical funding or collaboration announcement. No current contract implied.
Read on ossianix.co.uk ↗ - Media & events
Financial Times coverage on Ossianix – Lundbeck collaboration
Historical media coverage or conference presentation.
Read on ossianix.co.uk ↗ - Lundbeck
Berlingske – Danish newspaper coverage on Ossianix – Lundbeck collaboration
Historical funding or collaboration announcement. No current contract implied.
Read on ossianix.co.uk ↗ - Lundbeck
Ossianix receives milestone payment from Lundbeck for blood-brain barrier (BBB) antibody delivery technology
Historical funding or collaboration announcement. No current contract implied.
Read on ossianix.co.uk ↗
2016
- Media & events
Ossianix presented a poster at the CSHL meeting on Blood Brain Barrier 2016
Historical media coverage or conference presentation.
Read on ossianix.co.uk ↗ - Media & events
Our presentation at the GTC Boston Protein Discovery Summit
Historical media coverage or conference presentation.
Read on ossianix.co.uk ↗ - Media & events
Ossianix presents at PEGS Europe 2016
Historical media coverage or conference presentation.
Read on ossianix.co.uk ↗ - Media & events
Ossianix publishes a research article
Historical media coverage or conference presentation.
Read on ossianix.co.uk ↗ - Media & events
OSSIANIX USES SHARK-DERIVED ANTIBODIES TO CROSS THE BBB
Historical media coverage or conference presentation.
Read on ossianix.co.uk ↗
2015
- Media & events
Ossianix presents at the BBB at CSHL meeting on Blood Brain Barrier 2015
Historical media coverage or conference presentation.
Read on ossianix.co.uk ↗
2014
- Lundbeck
Ossianix Expands and Extends its Research Collaboration with Lundbeck on CNS Therapeutics 16 December 2014
Historical funding or collaboration announcement. No current contract implied.
Read on ossianix.co.uk ↗ - Media & events
BioCentury 28 September 2014: OSSIANIX: SHARK TEETH
Historical media coverage or conference presentation.
Read on ossianix.co.uk ↗ - Lundbeck
Ossianix Announces Strategic Research Collaboration with Lundbeck
Historical funding or collaboration announcement. No current contract implied.
Read on ossianix.co.uk ↗ - Media & events
Science center-housed biotech startup ossianix a shark of innovation, hiring 10
Historical media coverage or conference presentation.
Read on ossianix.co.uk ↗ - Lundbeck
Ossianix Announces Strategic Research Collaboration with Lundbeck
Historical funding or collaboration announcement. No current contract implied.
Read on ossianix.co.uk ↗
2012
- Lundbeck
Ossianix Announces Lundbeck Investment
Historical funding or collaboration announcement. No current contract implied.
Read on ossianix.co.uk ↗